{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:19:43Z","timestamp":1776370783973,"version":"3.51.2"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2847,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2007.01625.x","type":"journal-article","created":{"date-parts":[[2007,11,7]],"date-time":"2007-11-07T00:04:53Z","timestamp":1194393893000},"page":"27-38","source":"Crossref","is-referenced-by-count":31,"title":["Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions"],"prefix":"10.1155","volume":"62","author":[{"given":"D. R.","family":"Staskin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. V.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. V.","family":"Polishuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. R.","family":"Zinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,11,15]]},"reference":[{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","article-title":"The development of human benign prostatic hyperplasia with age","volume":"132","author":"Berry","year":"1984","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1464-410X.2005.05889.x","article-title":"Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries","volume":"97","author":"Irwin","year":"2006","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.eururo.2005.04.026","article-title":"Prevalence of the overactive bladder syndrome by applying the International Continence Society definition","volume":"48","author":"Temml","year":"2005","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1023\/A:1015292603884","article-title":"Common conditions of the aging male: erectile dysfunction, benign prostatic hyperplasia, cardiovascular disease and depression","volume":"33","author":"Zakaria","year":"2001","journal-title":"Int Urol Nephrol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB7|cit7","first-page":"S608","article-title":"Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder","volume":"8","author":"Kelleher","year":"2002","journal-title":"Am J Manag Care"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1464-410X.2004.05255.x","article-title":"Improved quality of life in patients with overactive bladder symptoms treated with solifenacin","volume":"95","author":"Kelleher","year":"2005","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1464-410X.2006.06068.x","article-title":"Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence","volume":"97","author":"Roehrborn","year":"2006","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.urology.2006.03.006","article-title":"Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia","volume":"68","author":"Kaplan","year":"2006","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB11|cit11","volume-title":"Agent Selection for Overactive Bladder Patients with and without Documented Comorbid Benign Prostatic Hyperplasia","author":"Jumadilova","year":"2005"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1524-4733.2005.00041.x","article-title":"Persistence and adherence of medications for chronic overactive bladder\/urinary incontinence in the California Medicaid Program","volume":"8","author":"Yu","year":"2005","journal-title":"Value Health"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.326.7394.841","article-title":"Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review","volume":"326","author":"Herbison","year":"2003","journal-title":"BMJ"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB14|cit14","first-page":"387","volume-title":"Proceedings from the 6th International Consultation on New Developments in Prostate Cancer and Prostate Diseases","author":"McConnell","year":"2005"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2004.05039.x","article-title":"Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder","volume":"94","author":"Lee","year":"2004","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-5347(05)66095-8","article-title":"A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence","volume":"166","author":"Davila","year":"2001","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","article-title":"Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence","volume":"62","author":"Dmochowski","year":"2003","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4065\/78.6.696","article-title":"Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects","volume":"78","author":"Appell","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0022-5347(05)64684-8","article-title":"Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence","volume":"168","author":"Dmochowski","year":"2002","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00345-005-0012-8","article-title":"Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials","volume":"23","author":"Dmochowski","year":"2005","journal-title":"World J Urol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1464-410X.2006.06658.x","article-title":"Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study","volume":"99","author":"Sand","year":"2007","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.ajog.2006.08.013","article-title":"The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of TRansdermal therapy In overactive bladder with oXybutynin trial","volume":"195","author":"Sand","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2006.01.007","article-title":"The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder","volume":"49","author":"Coyne","year":"2006","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1471-0528.1997.tb11006.x","article-title":"A new questionnaire to assess the quality of life of urinary incontinent women","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1464-410x.1999.00004.x","article-title":"Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine","volume":"83","author":"Kobelt","year":"1999","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1471-0528.2004.00129.x","article-title":"How much is enough and who says so? The case of the King's Health Questionnaire and overactive bladder","volume":"111","author":"Kelleher","year":"2004","journal-title":"BJOG"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2006.10.005","article-title":"Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder","volume":"51","author":"Dmochowski","year":"2007","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB30|cit30","first-page":"69","article-title":"Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine","volume":"2","author":"Pleil","year":"2001","journal-title":"Health Econ Prev Care"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0022-5347(05)00483-0","article-title":"Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction","volume":"175","author":"Abrams","year":"2006","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"issue":"Suppl. 2A","key":"10.1111\/j.1742-1241.2007.01625.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.urology.2006.05.045","article-title":"Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment","volume":"68","author":"Brubaker","year":"2006","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB34|cit34","volume-title":"Note for Guidance on the Clinical Investigation of Medicinal Products for the Treatment of Urinary Incontinence","author":"European Agency for the Evaluation of Medicinal Products and Committee for Proprietary Medicinal Products","year":"2002"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0302-2838(02)00061-1","article-title":"\u2018Quality of life\u2019 assessment of urination in elderly Japanese men and women with some medical problems using International Prostate Symptom Score and King's Health Questionnaire","volume":"41","author":"Okamura","year":"2002","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0302-2838(02)00438-4","article-title":"The relationships among filling, voiding subscores from International Prostate Symptom Score and quality of life in Japanese elderly men and women","volume":"42","author":"Okamura","year":"2002","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2007.01625.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1742-1241.2007.01491.x","article-title":"A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting","volume":"61","author":"Rosenberg","year":"2007","journal-title":"Int J Clin Pract"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2007.01625.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2007.01625.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T01:05:28Z","timestamp":1643331928000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2007.01625.x"}},"subtitle":["Transdermal oxybutynin for men with OAB"],"short-title":[],"issued":{"date-parts":[[2007,11,15]]},"references-count":37,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01625.x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1097217.553226","asserted-by":"object"}]},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11,15]]}}}